Search research articles
Contact Us
Filters
Showing results (281-290 of 311) with videos related to
Page
of 32
Sort By:
Annals of the Rheumatic Diseases
|
December 31, 2024
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer
Eden Sebbag, Juan Molina-Collada, Ramatoulaye Ndoye, et al.
Annals of the Rheumatic Diseases
|
February 1, 2025
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer
Eden Sebbag, Juan Molina-Collada, Ramatoulaye Ndoye, et al.
The Journal of Infection
|
February 7, 2023
Low to undetectable Omicron BQ.1.1 neutralization by patient's sera a month after initiation of AZD7442 600 mg
Franck Touret, Guillaume Martin-Blondel, Xavier de Lamballerie, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
November 9, 2023
Towards the Lowest Efficacious Dose: Results From a Multicenter Noninferiority Randomized Open-Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis in Remission
Joanna Kedra, Philippe Dieudé, Caroline Giboin, et al.
Clinical and Experimental Rheumatology
|
March 29, 2022
Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison
Chiara Baldini, Laurent Arnaud, Tadej Avčin, et al.
Annals of the Rheumatic Diseases
|
December 7, 2014
Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)
Raphaèle Seror, Hendrika Bootsma, Alain Saraux, et al.
Annals of the Rheumatic Diseases
|
November 19, 2020
Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial
Renaud Felten, Valérie Devauchelle-Pensec, Raphaèle Seror, et al.
Annals of the Rheumatic Diseases
|
June 17, 2025
Primary Sjögren's Disease: a review of unmet need, outcome measures, therapeutic advances and health economic impacts. Lessons from the NEw Clinical Endpoints in primary Sjögren's Syndrome: an Interventional Trial based on stratifYing patients (NECESSITY) Innovative Health Initiative (IHI)
Simon J Bowman, Raphaele Seror, Raphael Porcher, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
June 19, 2024
Preclinical in vivo assessment of the activity of AZD7442 anti-SARS-CoV-2 monoclonal antibodies against Omicron sublineages
Jean-Sélim Driouich, Maxime Cochin, Guillaume Lingas, et al.
RMD Open
|
November 1, 2022
Tolerance and efficacy of targeted therapies prescribed for off-label indications in refractory systemic autoimmune diseases: data of the first 100 patients enrolled in the TATA registry (TArgeted Therapy in Autoimmune Diseases)
Jacques-Eric Gottenberg, Aurore Chaudier, Yves Allenbach, et al.
Page
of 32
Search research articles
Search
Showing results (281-290 of 311) with videos related to
Sort By:
Page
of 32
Annals of the Rheumatic Diseases
|
December 31, 2024
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer
Eden Sebbag, Juan Molina-Collada, Ramatoulaye Ndoye, et al.
Annals of the Rheumatic Diseases
|
February 1, 2025
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer
Eden Sebbag, Juan Molina-Collada, Ramatoulaye Ndoye, et al.
The Journal of Infection
|
February 7, 2023
Low to undetectable Omicron BQ.1.1 neutralization by patient's sera a month after initiation of AZD7442 600 mg
Franck Touret, Guillaume Martin-Blondel, Xavier de Lamballerie, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
November 9, 2023
Towards the Lowest Efficacious Dose: Results From a Multicenter Noninferiority Randomized Open-Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis in Remission
Joanna Kedra, Philippe Dieudé, Caroline Giboin, et al.
Clinical and Experimental Rheumatology
|
March 29, 2022
Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison
Chiara Baldini, Laurent Arnaud, Tadej Avčin, et al.
Annals of the Rheumatic Diseases
|
December 7, 2014
Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)
Raphaèle Seror, Hendrika Bootsma, Alain Saraux, et al.
Annals of the Rheumatic Diseases
|
November 19, 2020
Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial
Renaud Felten, Valérie Devauchelle-Pensec, Raphaèle Seror, et al.
Annals of the Rheumatic Diseases
|
June 17, 2025
Primary Sjögren's Disease: a review of unmet need, outcome measures, therapeutic advances and health economic impacts. Lessons from the NEw Clinical Endpoints in primary Sjögren's Syndrome: an Interventional Trial based on stratifYing patients (NECESSITY) Innovative Health Initiative (IHI)
Simon J Bowman, Raphaele Seror, Raphael Porcher, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
June 19, 2024
Preclinical in vivo assessment of the activity of AZD7442 anti-SARS-CoV-2 monoclonal antibodies against Omicron sublineages
Jean-Sélim Driouich, Maxime Cochin, Guillaume Lingas, et al.
RMD Open
|
November 1, 2022
Tolerance and efficacy of targeted therapies prescribed for off-label indications in refractory systemic autoimmune diseases: data of the first 100 patients enrolled in the TATA registry (TArgeted Therapy in Autoimmune Diseases)
Jacques-Eric Gottenberg, Aurore Chaudier, Yves Allenbach, et al.
Page
of 32